Obstetrics, gynecology, andrology, sexual and reproductive health

Obesity, eating disorders

PubMed Free Full Text

Obesity: pharmacologic treatment

 

Australia

• Australian Family Physician
  • Pharmacotherapy for obesity [2017]

Canada

• Canadian Agency for Drugs and Technologies in Health
  • Pharmacoeconomic Review Report: Naltrexone Hydrochloride and Bupropion Hydrochloride (Contrave) [2020]
  • Clinical Review Report: Naltrexone Hydrochloride and Bupropion Hydrochloride (Contrave) [2020]
  • CADTH Canadian Drug Expert Committee Recommendation: Naltrexone Hydrochloride and Bupropion Hydrochloride (Contrave — Bausch Health, Canada Inc.) [2020]

Europe

• European Association for the Study of Obesity
  • 2014 EASO Position Statement on the Use of Anti-Obesity Drugs [2015]

• European Medicines Agency
  • Guideline on clinical evaluation of medicinal products used in weight management [2016]

International

• BMC Medicine
  • Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review [2016]

• Current Obesity Reports
  • Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? [2021]

• Diabetology & Metabolic Syndrome
  • The best drug supplement for obesity treatment: a systematic review and network meta-analysis [2021]

Saudi Arabia

• Scientific World Journal
  • Safety Evaluation of Local Weight-Gain Formulas in the Saudi Arabian Markets [2015]

United Kingdom

• National Institute for Health and Care Excellence
  • Liraglutide for managing overweight and obesity [2020]
  • Obese, overweight with risk factors: liraglutide (Saxenda) [2017]
  • Naltrexone–bupropion for managing overweight and obesity [2017]

United States

• Current Opinion in Endocrinology, Diabetes and Obesity
  • Pharmacotherapy in Pediatric Obesity: Current Evidence and Landscape [2021]

• Endocrine Practice
  • Anti-obesity Medication Use Among Adults with Overweight and Obesity in the United States: 2015–2018 [2021]

• Endocrine Society
  • Pharmacological management of obesity: an Endocrine Society clinical practice guideline [2015]

• Expert Opinion on Drug Safety
  • The risk of cardiovascular complications with current obesity drugs [2020]

• Expert Opinion on Pharmacotherapy
  • The limits and challenges of antiobesity pharmacotherapy [2020]
  • Anorectic state of obesity medications in the United States. Are leaner times ahead? [2020]

• Journal of Women's Health
  • Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists [2021]

• Obesity
  • Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010 [2015]

{Related topics}

• Guidelines
  • Obesity